Roche sees fall in FY23 earnings on ‘sharp decline’ in COVID products sales
FY22 Core EPS rose +2% on CHF basis Y/Y to CHF20.30 (+5% Y/Y at constant exchange rates - CER). Group...
Read moreFY22 Core EPS rose +2% on CHF basis Y/Y to CHF20.30 (+5% Y/Y at constant exchange rates - CER). Group...
Read moreFY Non-GAAP EPS of CHF20.30. Revenue of CHF63.28B (+0.8% Y/Y). Core operating profit increased by 3% to CHF 22.2B (1%...
Read moreIf approved by shareholders, this would be the 36th consecutive dividend increase. Outlook for 2023 Due to the sharp decline...
Read moreAd hoc announcement pursuant to Article 53 of the Six Exchange Regulation Listing Rules Lausanne, 2 February 2023 Adjusted revenue...
Read morePages Report] Rising demand for Pharmaceuticals Industry will drive the Congestive Heart Failure (Chf) Treatment Devices segment growth over the...
Read moreFed drowned US Dollar with dovish hike, downbeat US data also favor USD/CHF bears. Monetary policy decision from ECB, BoE...
Read moreUSD/CHF has printed a fresh two-week low at 0.9070 as Fed scales down the policy tightening pace. The downbeat US...
Read moreThe USD/CHF is trapped within a 140 pip area, trendless and fluctuating around the 20-day EMA. USD/CHF Price Analysis: The...
Read moreNovartis (NYSE:NVS) board proposes a dividend payment of CHF 3.20/share for 2022, up 3.2% from CHF 3.10/share in the prior...
Read moreNet sales grew +4% (cc 1 , -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales...
Read more